Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Morphotek, Inc.
Morphotek, Inc. Receives $1.7M in Funding from the U.S. Department of Defense to Develop Therapeutic Antibodies Against Microbial Bioweapons
July 16th, 2008
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced that the company has received $1.7M funding approval from the U.S. Department of Defense to support the development of biologic-based monoclonal antibody (mAb) therapies against staphylococcal-derived pathogens. The proceeds will be used to help further develop mAbs targeting staphylococcal toxins as well as staph itself for the treatment of infectious diseases. By employing Morphotek's proprietary antibody technologies, the company has developed multiple mAbs that are able to bind and neutralize the toxic effects elicited by microbial pathogens and is applying its technology to generate...
Source: Vaccine Weekly (2008-07-16)
|
